Leschke Jack M, Lozen Andrew, Kaushal Mayank, Oni-Orisan Akinwunmi, Noufal Mazen, Zaidat Osama, Pollock Glen A, Mueller Wade M
Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USA.
Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Neurocrit Care. 2017 Aug;27(1):11-16. doi: 10.1007/s12028-016-0350-y.
Currently, a complete understanding of post-ventriculostomy hemorrhagic complications in subarachnoid hemorrhage due to ruptured aneurysms remains unknown. The present study evaluates the impact of periprocedural risk factors on rates of external ventricular drain (EVD)-associated hemorrhage in the setting of endovascular treatment of intracranial aneurysms.
A retrospective chart review of 107 patients who underwent EVD placement within 24 h of endovascular coiling was performed. CT of head without contrast was obtained after drain placement and before endovascular treatment. Post-procedural CT was also obtained within 48 h of embolization and was reviewed for new/worsened track hemorrhages. Chi-squared test was used in evaluation.
Ninety-three of the 107 patients reviewed met the inclusion criteria. Four (25%) of the 16 patients on antiplatelet medications at presentation experienced post-EVD hemorrhage compared to 11 (14.3%) of 77 that were not (p = 0.29). Of the 13 patients given intraprocedural antiplatelets, 3 (23.1%) demonstrated hemorrhage compared to 12 (15%) of 80 not administered these medications (p = 0.46). Further, of 36 patients with intraprocedural anticoagulation, 6 (16.7%) exhibited hemorrhage compared to 9 (15.8%) of 57 in those without (p = 0.91). In 17 patients who received DVT prophylaxis, 2 (11.8%) exhibited hemorrhage compared to 13 (17.1%) of 76 who did not (p = 0.59). No post-EVD hemorrhage had attributable neurologic morbidity.
Our results, demonstrating no significant risk factor related to EVD-associated hemorrhage rates, support the safety of EVD placement in the peri-endovascular treatment period.
目前,对于因动脉瘤破裂导致蛛网膜下腔出血患者脑室造瘘术后出血并发症的全面认识仍不清楚。本研究评估了围手术期危险因素对颅内动脉瘤血管内治疗过程中外引流(EVD)相关出血发生率的影响。
对107例在血管内栓塞24小时内接受EVD置管的患者进行回顾性病历审查。在引流管放置后和血管内治疗前进行头部非增强CT检查。栓塞术后48小时内也进行了术后CT检查,并对新出现/加重的引流道出血进行了评估。采用卡方检验进行评估。
107例接受审查的患者中有93例符合纳入标准。16例入院时服用抗血小板药物的患者中有4例(25%)发生EVD术后出血,而77例未服用抗血小板药物的患者中有11例(14.3%)发生出血(p = 0.29)。13例术中接受抗血小板治疗的患者中有3例(23.1%)出现出血,而80例未接受这些药物治疗的患者中有12例(15%)出现出血(p = 0.46)。此外,36例术中接受抗凝治疗的患者中有6例(16.7%)出现出血,而57例未接受抗凝治疗的患者中有9例(15.8%)出现出血(p = 0.91)。17例接受深静脉血栓预防的患者中有2例(11.8%)出现出血,而76例未接受预防的患者中有13例(17.1%)出现出血(p = 0.59)。没有EVD术后出血导致神经系统发病。
我们的结果表明没有与EVD相关出血发生率相关的显著危险因素,支持了在血管内治疗期间放置EVD的安全性。